AliveGen Live stronger and longer
AliveGen Live stronger and longer

R&D Product Pipeline


Phase 1a and 1b clinical trials successfully completed 


Press Release. THOUSAND OAKS, Calif.--(BUSINESS WIRE)--"AliveGen Announces Successful Completion of Phase 1b Multiple-Ascending Dose Clinical Trial for ALG-801". March 18, 2024 08:00AM.



Preclinical and CMC development 


Multiple Novel Candidates

Preclinical development

Print | Sitemap
Copyright © AliveGen USA, Inc. All Rights Reserved.